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The impact of Parkinson’s disease (PD) on psychological status and quality of life (QoL)may vary depending on age of disease onset.
The aim of this study was to compare psychological symptoms and disease-specific QoL between early onset versus the rest of the
PD patients. A total number of 140 PD patients with the mean current age of 61.3 (SD = 10.4) yr were recruited in this study. PD
patients with the onset age of ≤50 yr were defined as “early-onset” (EOPD) group (𝑛 = 45), while the ones with >50 yr at the time
of diagnosis were categorized as the “typical-onset” (TOPD) patients (𝑛 = 95). Different questionnaires and scales were used for
between-group comparisons including PDQ39, HADS (hospital anxiety and depression scale), FSS (fatigue severity scale), MNA
(mininutritional assessment), and the UPDRS. Depression score was significantly higher in EOPD group (6.3 (SD = 4.5) versus
4.5 (SD = 4.2), 𝑃 = 0.02). Among different domains of QoL, emotion score was also significantly higher in the EOPD group (32.3
(SD = 21.6) versus 24.4 (SD = 22.7),𝑃 = 0.05). Our findings showedmore severe depression andmore impaired emotional domain
of QoL in early-onset PD patients. Depression and anxiety play an important role to worsen QoL among both EOPD and TOPD
patients, while no interaction was observed in the efficacy of these two psychiatric symptoms and the onset age of PD patients.
1. Introduction
Parkinson’s disease (PD) is mostly diagnosed in the elderly
though a substantial minority of the patients develop symp-
toms before 50 years of age who are called early-onset
Parkinson’s disease (EOPD) patients. Patients with EOPD
have been detected with rather different characteristics;
hence, a different impact of the disease on their lives is
expected [1–4]. By developing PD, patients might experience
premature aging, increasing dependency, and impairment of
occupational performance. The longer the duration of the
disease is, the higher physical, economic, and psychological
burden of PD often occurs in patients, especially in younger
adults with greater socioeconomic responsibilities. On the
other hand, treatment-induced motor complications would
be higher among the EOPD patients and may contribute to a
greater degree of physical impairment and social squeals [2,
3, 5, 6]. Although most of the previous studies have reported
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poorer quality of life (QoL) in PD patients with earlier age of
onset, some findings are still controversial [2, 5, 7–11]. One
possible explanation refers to the fact that different motor
and nonmotor determinants might affect QoL differently
among the EOPD and typical-onset (TOPD) population.
More precisely, there are several important variables thatwere
not adjusted between EOPD and TOPD groups in previous
studies such as the dosage of levodopa and PD severity.
Growing evidence shows that psychological symptoms
and emotional wellbeing play important roles in lowering of
QoL in PD patients with earlier disease onset. Therefore, for
the sake of better comparison of QoL and its determinants
between EOPD and TOPD patients, this study was designed
to compare psychological symptoms and disease-specific
QoL between EOPD and TOPD patients with similar disease
severitymeasured by scales such as theHoehn andYahr stage.
Furthermore, a varied list of characteristics were assessed
and compared between the two groups including motor
and nonmotor symptoms (such as depression and anxiety),
fatigue, and nutritional status to understand how differently
these factors might influence QoL with regard to the age of
disease onset.
2. Methods and Materials
2.1. Subjects and Setting. A total number of 140 idio-
pathic Parkinson’s disease (IPD) subjects were consecutively
recruited from one major outpatient referral Movement
Disorder Clinics in Tehran, Iran, during 2011-2012.The study
protocol was approved by the Ethics Committee of the
Neurology Department at the Firoozgar Clinical Research
Development Center (FCRDC) in Tehran, Iran. All col-
lected data was stored and treated according to the ethical
guidelines of this research center. Participation in this study
was voluntary and each participant was informed about the
aims and objectives before the enrollment. The identity of
research participants was protected, since the data files were
anonymous and all names were omitted.
All cases were enrolled into the study after a thorough
physical examination by a neurologist specialized in move-
ment disorders and when the UK brain bank criteria for
the diagnosis of IPD [12] were met. Patients with atypical
parkinsonism including multiple system atrophy (MSA),
progressive supranuclear palsy (PSP), and vascular or drug-
induced parkinsonism were not eligible. Moreover, those
with moderate to severe dementia (minimental status exam
(MMSE) < 24) [13] were also excluded from the study. Using
the conventional cut-off value of 50 [2, 14, 15], recruited PD
patients with the onset age of ≤50 yr were defined as “early-
onset” (EO) group (𝑛 = 45), whereas the ones with >50 yr at
the time of diagnosis were categorized as the “typical-onset”
(TO) PD patients (𝑛 = 95). Onset age was recorded as the age
when PD-related symptoms had firstly started using patients’
initial medical records at the clinic.
2.2. Assessments. A movement disorder specialist and a
group of trained medical students and general physicians
performed data collection through interviews and clinical
measurements. All clinical assessments were performed dur-
ing the “On” state anddifferent questionnaires and scaleswere
used to provide data for between-group comparisons. Demo-
graphic information consisted of baseline variables, educa-
tional status, and comorbidities. PD-related characteristics
including disease duration (time passed from diagnosis),
measures of disease severity such as the Unified Parkinson’s
Disease Rating Scale (UPDRS) consisting of four sections
on nonmotor symptoms (part I), activities of daily living
(ADL) (part II), motor examination (part III) and drug
complications (part IV) [16], Hoehn and Yahr stage [17],
and Schwab and England activity of daily living (ADL) scale
[18] were recorded. Higher scores obtained in UPDRS refer
to a more severe condition in PD patients. Current daily
dosage of levodopa was measured according to their latest
treatment protocol at the time of assessment extracted from
patients’ medical records. In addition, the weight-adjusted
daily dose of levodopa (mg/kg) was calculated as cumulative
daily dosage of levodopa in mg divided by body weight in kg
for each recruited patient.
We used the validated Persian version of the fatigue
severity scale (FSS) [19] in order to measure fatigue severity.
This instrument contains nine questions on severity of fatigue
during the past week scored from 1 to 7 and a total score,
which is obtained by averaging the scores of all items
where the higher ones show more severe fatigue [20]. For
psychological assessment, the validated Persian version of the
Hospital Anxiety andDepression Scale (HADS)was also used
[21]. This tool has two sections for depression and anxiety,
each of which contains seven questions scored through a
range of 0–21 points where higher scores demonstrate worse
condition [22].The Persian version of the Parkinson’s disease
quality of life questionnaire (PDQ-39) was used to measure
health-related quality of life (HRQoL) in PD patients [23, 24].
The PDQ-39 contains 39 Likert-scale items assessing eight
domains of disease-related quality of life (QoL) in PD pop-
ulation including mobility, activities of daily living (ADL),
emotionalwellbeing, stigma, social support, cognitions, com-
munication, and bodily discomfort. The scores range from 0
to 100 and the higher a patient scores, the poorer QoL he/she
has experienced [25]. For nutritional status, we used theMini
Nutritional Assessment (MNA) questionnaire comprising 18
items including anthropometricmeasurements on bodymass
index (BMI), arm, and calf circumferences. The maximum
score in the MNA questionnaire is 30 points, and the higher
someone scores, the better nutritional status he/she has [26].
2.3. Statistical Analysis. Data were analyzed using SPSS
software version 22.0 (IBM., Chicago, IL, USA). In order to
describe continuous and qualitative variables, mean (stan-
dard deviation (SD)) and frequency (percentage) were used,
respectively. The Kolmogorov-Smirnov test was used to
check the normality of distribution for numeric variables.
In case of skewed distributions, median and interquartile
range (IQR) was used for descriptive reports. For univariate
comparisons, either independent 𝑡-test or Mann-Whitney𝑈-
test was applied to compare themean values ormean ranks of
the normally or nonnormally distributed numeric variables
between the two groups, respectively. The Chi square test
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Figure 1: Linear correlation of the age of disease onset with (a) depression and (b) anxiety scores among the subjects with idiopathic
Parkinson’s disease.
was performed for between-group comparisons of nominal
or categorical variables. Spearman correlation was used to
evaluate the linear relationship of the onset age of PD with
depression and anxiety scores. Additionally, we applied par-
tial correlation to control the association between the onset
age and depression and anxiety by PD duration. For multi-
variate analysis, linear regression model was applied to assess
whether the effect of EOPD on the outcome scores (QoL,
depression, anxiety, fatigue, and nutritional status) remains
significant after adjustment for potential confounders. Sex,
educational level, and comorbidity indicator were selected
as well-known confounders to affect psychiatric symptoms
and QoL. Although as an intermediary variable, Hoehn and
Yahr stage was also included into the model to assess how
independent was the effect of EOPD on outcome variables
regardless of disease severity as another known determinant
factor to influence psychiatric symptoms and QoL in PD.
For use in multivariate analysis, a new variable named
“comorbidity index” was created by adding up the number
of comorbidities each patient had consisting of hypertension,
interstitial heart disease, stroke or transient ischemic attack,
diabetes, osteoarthritis, and chronic obstructive pulmonary
disease. In all analytical procedures, a two-sided 𝑃 value of
<0.05 was considered as the statistical significant level to
reject the corresponding null hypothesis.
3. Results
3.1. Demographic Characteristics. Of 140 patients who com-
pleted the study, 45 had onset of PD before age 50 (EOPD)
and 95 had onset age after 50 years (TOPD). The average
current age of the whole study population was 61.3 (SD =
10.4) yr and the range for age of onset was 20–50 years in
the EOPD and 51–77 years in the TOPD group. Table 1 shows
their baseline, clinical, and sociodemographic characteristics.
The male preponderance was higher in the TOPD group
(2.39) compared to that of the EOPD (1.65); however, sex
distribution was not significantly different between the two
groups (𝑃 = 0.326). As expected, duration of PD was signifi-
cantly longer among the EOPD patients [8.5 (SD = 7.7) versus
5.9 (SD = 3.7), 𝑃 = 0.035]. Nevertheless, no significant differ-
ence was found in the severity of PD assessing by neither the
Hoehn and Yahr stage (EOPD 2.0 (IQR = 2.0) versus TOPD
2.0 (IQR= 1.5),𝑃 = 0.923), nor the Schwab and EnglandADL
score (EOPD 80.4% (SD = 19.6) versus TOPD 82.4% (SD =
15.1), 𝑃 = 0.553) and nor the total UPDRS score (EOPD 34.3
(SD = 21.0) versus TOPD 30.6 (SD = 15.2), 𝑃 = 0.326). The
EOPD patients received a significantly higher daily dosage of
levodopa (1000 (IQR = 710)mg versus 750 (IQR = 500)mg,
𝑃 = 0.030) even after weight-adjustment (13.4 (IQR =
12.2)mg/kg versus 10.4 (IQR = 6.7)mg/kg, 𝑃 = 0.040).
3.2. Psychiatric Features. Table 2 summarizes the results for
comparing anxiety, depression, and fatigue scores between
the two study groups. Depression score was significantly
higher among the EOPD patients (6.3 (SD = 4.5) versus 4.5
(SD = 4.2), 𝑃 = 0.02), while anxiety and fatigue scores failed
to show any significant difference between the two groups.
Based on the cutoff value of ≥8 for the HADS scores [27],
the prevalence of depression was significantly higher in the
EOPD group (40% versus 21%, OR = 2.5 (95% CI 1.2 to 5.4);
𝑃 = 0.019). A higher proportion of anxious patients were
seen in the EOPD group (47% versus 35%, OR = 1.6 (95%
CI 0.8 to 3.4); 𝑃 = 0.176); however, the difference was not
statistically significant.
As shown in Figure 1, Spearman correlation statistic
showed a significant inverse correlation between the age at
PD onset and both depression (Spearman rho = −0.226, 𝑃 =
0.007) and anxiety (Spearman rho = −0.171, 𝑃 = 0.043)
scores. The results of partial correlation demonstrated that
these associations remained statistically significant even after
controlling for the duration of PD (for depression: 𝑟 =
−0.214, 𝑃 = 0.011; for anxiety: 𝑟 = −0.167, 𝑃 = 0.049).
Fatigue score was not correlated with the onset age of PD
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Table 1: Baseline, clinical, and sociodemographic characteristics of the early-onset and typical-onset Parkinson’s disease patients.
Characteristics Early onset (𝑛 = 45) Typical onset (𝑛 = 95) 𝑃 value
Gender no. (%)
Female 17 (37.8) 28 (29.5) 0.326
Male 28 (62.2) 67 (70.5)
Level of education∗∗ no. (%)
Illiterate 2 (4.7) 10 (10.5)
0.137Primary and/or secondary 11 (25.6) 24 (25.3)
High School/Diploma 17 (39.5) 21 (22.1)
College and/or University 13 (30.2) 40 (42.1)
Duration of disease (yr)
Mean (SD) 8.5 (7.7) 5.9 (3.7) 0.035∗
UPDRS score mean (SD)
Part I-mental 2.3 (2.8) 1.8 (1.9) 0.407
Part II-ADL 12.5 (7.6) 10.6 (6.8) 0.148
Part III-motor 15.7 (11.5) 15.2 (7.6) 0.490
Part IV-complications 4.0 (3.4) 3.3 (2.4) 0.198
Total 34.3 (21.0) 30.6 (15.2) 0.326
Hoehn and Yahr Stage
Median (IQR) 2.0 (2.0) 2.0 (1.5) 0.923
Schwab and England activities of daily Living Score (%)
Mean (SD) 80.4 (19.6) 82.4 (15.1) 0.553
Levodopa dose (mg) median (IQR)
Cumulative Daily Dose 1000.0 (710.0) 750.0 (500.0) 0.030∗
Weight-adjusted daily dose 13.4 (12.2) 10.4 (6.7) 0.040∗
∗Difference is statistically significant at the 0.05 level (2-tailed).
∗∗Data on education level is not available for two patients (missing value) and valid relative percentages are reported.
Table 2: Univariate and multivariate comparison of the mean (standard deviation (SD)) scores of different motor, nonmotor, and quality of
life (PDQ-39) scales between subgroups of Parkinson’s disease (PD) patients regarding the age of disease onset.
Scale Domain Early-onset(𝑛 = 45)
Typical-onset
(𝑛 = 95)
Univariate comparison Multivariate comparison
Unadjusted 𝐵
(95% CI) 𝑃 value
Adjusted 𝐵
(95% CI) 𝑃 value
PDQ39
Mobility 26.6 (26.8) 26.9 (24.5) −0.3 (−9.4–8.7) 0.94 −2.1 (−9.4–5.3) 0.58
Activities of daily living (ADL) 24.8 (25.0) 21.9 (20.6) 2.9 (−5.2–11.0) 0.48 1.8 (−5.3–8.9) 0.61
Emotional wellbeing 32.3 (21.6) 24.4 (22.7) 7.9 (−0.1–15.9) 0.05∗ 6.3 (−1.3–14.0) 0.11
Stigma 25.1 (26.9) 19.8 (24.6) 5.3 (−3.7–14.4) 0.25 5.6 (−4.0–15.1) 0.25
Social support 9.6 (15.7) 6.2 (12.2) 3.3 (−1.8–8.4) 0.20 0.2 (−4.4–4.9) 0.93
Cognitive impairment 16.7 (18.1) 16.8 (17.9) −0.1 (−6.5–6.3) 0.97 0.1 (−6.4–6.5) 0.99
Communication 18.0 (22.6) 11.9 (14.1) 6.0 (−0.1–12.2) 0.06 3.2 (−2.4–8.8) 0.26
Bodily discomfort 20.4 (20.2) 20.7 (21.6) −0.3 (−7.9–7.3) 0.93 −1.9 (−9.0–5.2) 0.60
Total 21.9 (14.6) 19.0 (13.5) 2.9 (−2.1–7.8) 0.25 1.6 (−2.8–6.0) 0.49
HADS Anxiety 7.5 (4.7) 6.3 (5.3) 1.2 (−0.6–3.1) 0.18 1.2 (−0.6–3.0) 0.20
Depression 6.3 (4.5) 4.5 (4.2) 1.8 (0.3–3.3) 0.02∗ 1.4 (0–2.9) 0.05∗
FSS Fatigue 4.7 (1.8) 4.4 (1.9) 2.8 (−3.4–8.9) 0.38 2.2 (−3.5–8.0) 0.48
MNA Nutritional status 24.4 (4.3) 25.5 (2.8) −1.1 (−2.3–0.1) 0.07 −0.9 (−2.0–0.2) 0.10
CI: confidence interval.
∗Difference is statistically significant at the 0.05 level (2-tailed).
(Multivariate adjustment has been performed considering sex, education level, comorbidity index, and Hoehn and Yahr stage as potential confounders).
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Table 3: Multivariate linear regression model for the effect of EOPD on health-related quality of life (QoL) score and its interactions with
other determinant factors.
Scales/Variables Coefficients Wald Chi2 95% CI for 𝐵 𝑃 value
𝐵 SEM Lower bound Upper bound
EOPD −3.7 15.7 0.1 −34.3 27.1 0.814
Female sex 2.9 1.7 3.0 −0.4 6.2 0.082
Education level
Illiterate 0 (ref.) — — — — —
Primary and/or Secondary −3.6 2.8 1.6 −9.1 2.0 0.208
High School/Diploma −2.8 2.9 1.0 −8.4 2.8 0.323
College and/or University −3.8 2.8 1.8 −9.3 1.7 0.176
Comorbidity index 0.2 0.8 0.1 −1.4 1.8 0.812
Hoehn & Yahr stage 0.8 0.9 0.8 −1.0 2.7 0.384
Nutritional status (MNA score) −0.5 0.4 1.8 −1.3 0.2 0.184
Interaction with EOPD 0.1 0.5 0.0 −0.9 1.2 0.829
Anxiety (HADS score) 0.6 0.2 8.9 0.2 1.0 0.003∗
Interaction with EOPD 0.2 0.4 0.2 −0.6 0.9 0.695
Depression (HADS score) 1.5 0.3 26.7 0.9 2.0 <0.001∗
Interaction with EOPD −0.5 0.5 0.9 −1.5 0.5 0.344
Fatigue (FSS score) 0.1 0.1 3.3 −0.0 0.2 0.071
Interaction with EOPD 0.0 0.1 0.0 −0.2 0.2 0.846
∗Statistically significant factor at the significance level of 0.05 (2-tailed).
(Multivariate adjustment has been performed considering sex, education level, comorbidity index, and Hoehn and Yahr stage as potential confounders).
both before and after adjustment for disease duration (𝑃 =
0.279 and 0.594, resp.). As shown in Table 2, multivariate
adjustment was performed to compare the comprehen-
sive list of psychiatric symptoms and fatigue between the
two study groups. Multivariate linear regression modeling
demonstrated that the EOPD patients had approximately 1.4
unit higher depression score even after adjustment for sex,
education level, comorbidity index, and the Hoehn and Yahr
stage as the possible proxy for disease severity (𝐵 = 1.42 (95%
CI:−0.01 to 2.85),𝑃 = 0.051). However, other outcomes failed
to show any significant difference between the EOPD and
TOPD patients after multivariate adjustments (all 𝑃 > 0.05).
3.3. Health-Related Quality of Life (HRQoL). The scores for
different domains of the PDQ-39 questionnaire and theMNA
scale for nutrition are listed in Table 2. The total score of
the PDQ-39 (EOPD 21.9 (SD = 14.6) versus TOPD 19.0 (SD
= 13.5), 𝑃 = 0.25) and the MNA (EOPD 24.4 (SD = 4.3)
versus TOPD 25.5 (SD = 2.8), 𝑃 = 0.07) was not signifi-
cantly different between the two study groups. However, the
EOPD patients had significantly worse emotional wellbeing
compared to the TOPD group (EOPD 32.3 (SD = 21.6) versus
TOPD 24.4 (SD = 22.7), 𝑃 = 0.05). Further multivariate
linear regression analysis was performed to assess the factors
that affect HRQoL (total score of the PDQ-39) and their
interactions with study groups (EOPD versus TOPD). As
shown inTable 3, EOPDwas not an independent determinant
factor for QoL in PD population (𝑃 = 0.815). Anxiety (𝐵 =
0.6 (95% CI: 0.2–1.0), 𝑃 = 0.003) and depression (𝐵 = 1.5
(95% CI: 0.9–2.0), 𝑃 < 0.001) significantly affected QoL in
entire PD population, while no significant interaction was
found between psychiatric symptoms, fatigue and nutritional
score with the grouping variable (EOPD versus TOPD) in
their effects on QoL score.
Sensitivity analysis was performed to check the variability
of the findings when the cutoff point for onset age was
changed. Neither lowering the cutoff value for the onset age
to 45 yr (EOPD (𝑛 = 28): 23.1 (SD = 15.3) versus TOPD
(𝑛 = 112): 19.2 (SD = 13.5), 𝑃 = 0.179) nor increasing it
to 55 yr (EOPD (𝑛 = 71): 21.9 (SD = 14.4) versus TOPD
(𝑛 = 69): 18.0 (SD = 13.1), 𝑃 = 0.100) did result in significant
difference in the total HRQoL score between the two study
groups. Multivariate linear regression analysis was also rerun
while a younger age of 45 yr was selected to define EOPD,
which showed no significant effect for the grouping variable
(EOPD versus TOPD) on the HRQoL score (𝐵 = 2.8 (95%
CI: −30.2–35.8), 𝑃 = 0.867). In contrast, when the cutoff
age was moved to a higher value of 55 yr, the new defined
EOPD showed significantly lower PDQ-39 score in the same
multivariate regression model (𝐵 = −35.8 (95% CI: −68.9–
−2.7), 𝑃 = 0.034).
4. Discussion
Our results suggest that patients with EOPD experience
worse condition in some psychological features mainly
depression compared to the TOPD group. While disease
duration was significantly longer and daily dosage of lev-
odopa received by patients was higher among the EOPD
group, disease severity did not significantly differ between
the two groups which further highlights the importance
of the independent psychosocial burden in PD. However,
this nonsignificant difference in PD severity could be also
due to the rather small sample size in each study group,
6 Parkinson’s Disease
too. In line with previous studies depression score was
significantly higher among the EOPD patients [2, 7, 28–
30]. Besides, our study demonstrates that this difference
remains significant, although statistically borderline, after
multivariate adjustment for sex, education level, comorbidity
burden, and the Hoehn and Yahr stage. This highlights the
role of psychosocial factors apart from the motor features
of the disease, including role expectations. Schrag et al.
suggest that older patients are more compatible with physical
impairments and employment issues such as early retirement
[2]. Findings from another study by Starkstein et al. suggest
that EOPD patients have higher frequency of depression and
their depression associates with cognitive impairments while
late-onset patients showed lower frequency of depression
which was mainly associated with activities of daily living
[29].We showed that anxiety score had an inverse correlation
with the onset age of PD; however, the difference among
two groups did not reach significant level as also showed
by Schrag et al. [2]. Our study is one of the few to evaluate
the correlation between fatigue score and onset age of PD,
which was not statistically significant. Nonetheless, Shulman
et al. declared that more than half of the times, presence of
depression, anxiety, and fatigue is not even identified [31].
We assessed health-related quality of life using the PDQ-
39 andnutritional status bymeans of theMNAscores, none of
which was significantly different between EOPD and TOPD
groups. Two other studies done by Knipe et al. [7] and Schrag
et al. [2] showed that total score of PDQ-39 was significantly
worse in young-onset patients. More detailed comparison
reveals that Knipe et al. [7] have used the cutoff age of
45 yr to define EOPD group. In our sensitivity analysis, the
cutoff value of 45 yr for definition of EOPD also failed to
show any significant independent effect on QoL. We must
also acknowledge the higher sample size in the similar study
performed by Knipe et al. [7] that had higher statistical power
to show small differences in QoL scores between the EOPD
and TOPD groups. However, similar to Knipe et al. [7] we
also demonstrated that the score on “emotional wellbeing”
as a domain of the PDQ-39 was significantly poorer in
EOPD patients. This further highlights the importance of
the psychological aspects of PD among the younger patients.
Knipe et al. suggested that the difference in quality of life
between EOPD versus TOPD patients could originate from
the higher levels of depressive mood in the former group
[7]. Results frommultivariate regression analysis in our study
showed that psychiatric features, namely, depression and
anxiety, were the factors that mainly affected QoL in the
whole PD population. This association, however, was found
to be independent of onset-age and the interaction terms
between depression, anxiety, fatigue, and nutritional status
with EOPD/TOPD were not significant. In other words,
depression and anxiety play a considerable role to worsen
QoL among both EOPD and TOPD patients.
Our study is one of the few attempts to compare a
comprehensive list of symptoms and conditions between the
EOPD and TOPD patients with a fairly deeper exploration
of the determinant factors of QoL in each subgroup. Our
study has described a previously unstudied population of
Iranian people with PD using validated Persian versions
of assessment scales. Moreover, we were able to include a
good representation of different ages and genders in this
PD population. As another point of interest, the levodopa
cumulative dose in our study refers only to L-Dopa itself and
not the other dopaminergic drugs and is not confounded by
the agonists’ effect on mood. Yet there are some limitations
as well including the rather small sample size and cross-
sectional design of the study. Moreover, disease duration was
significantly different whichmight have affected psychosocial
aspects of the disease. We tried partial correlation analysis
in order to adjust potential confounders though. Having
recruited patients from an outpatient tertiary clinic might
have induced a selection bias through which undiagnosed
patients are missed (potentially those with lower disease
severity), as well as those end-stage hospitalized PD patients.
This should be considered while generalizing our findings.
In conclusion, our findings draw more attention to the
important phenotypic differences between the EOPD and
TOPDpatients. Since depression ismore common in younger
PD patients which consequently affects QoL, its screening
and further interventions seem necessary. Depression and
anxiety found to be the most important determinants of
QoL in both EOPD and TOPD patients. Physicians need
to focus more on nonmotor symptoms of PD including
depression and anxiety that mainly worsen QoL. Accurate
and timely diagnosis of depression and anxiety is crucial to
improve QoL in PD patients as early as possible since these
symptoms could be evenmore frequently seen in younger PD
patients. Besides, it seems rational that people who live with
PD patients such as their caregivers become informed about
depressive symptoms and try to diminish psychosocial stress
and burden as well.
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